GSK plc GSK will report its second-quarter earnings on Jul 31, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $9.5 billion and $1.00 per share, respectively.

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

GlaxoSmithKline Is Moving Forward After Woeful Performance Jul. 08, 2014 5:27 PM ET GSK plc (GSK) Stock AZN , MRK , NVS , PFE , INVA , GSK 8 Comments Options Calling ...

GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%.

GSK is a rare undervalued stock in the frothy pharmaceutical sector. It's demonstrating strong operating performance and expects record sales for Shingrix this year.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...